Risankizumab

Risankizumab 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Crohn Disease、Perianal Fistula、Perianal Fistula Due to Crohn's Disease、Perianal Crohn's Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Risankizumab 研究

• Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

  III 期招募中美国NCT06274554

• Risankizumab in Children With Crohn's Disease (RisaKids)

  不适用招募中IsraelNCT06298188

• Real-World Study of IL-23 Inhibitors in Active Crohn's Disease

  不适用招募中中国NCT07545317

• Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

  I 期招募中PolandNCT07258745

• Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis

  不适用招募中日本NCT07136116

• Risankizumab for Refractory Perianal Fistulizing Crohn's Disease

  IV 期招募中日本NCT07872449

• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  III 期招募中美国奥地利比利时加拿大NCT07499232

• Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications

  不适用招募中美国NCT04846959

• SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)

  不适用招募中荷兰NCT07021495

• Fluorescence Imaging of Risankizumab-800CW in Inflammatory Bowel Disease

  I 期 / II 期招募中荷兰NCT06606808

• A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting

  不适用招募中意大利NCT07073079

• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

  II 期招募中美国NCT07138898

• PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease

  IV 期招募中加拿大NCT05928039

• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

  II 期招募中美国加拿大Czechia法国NCT06865105

• Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

  不适用招募中英国NCT07166315

• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

  III 期招募中美国澳大利亚加拿大法国NCT06100744

• Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis

  不适用招募中德国NCT06764706

• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  II 期招募中美国加拿大Israel日本NCT07697456

• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  III 期招募中美国比利时Bulgaria加拿大NCT05995353

• A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult Participants

  I 期招募中美国NCT07466550

• PsoBest - The German Psoriasis Registry

  不适用招募中德国NCT01848028

• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  II 期招募中美国奥地利比利时BulgariaNCT06548542

• Ibd CAncer and seRious Infections in France (I-CARE 2)

  不适用招募中法国NCT06089590

• Prevention of Postoperative Endoscopic Recurrence With Endoscopy-driven Versus Systematic Biological Therapy

  IV 期招募中比利时意大利NCT05169593

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。